The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The CYP2D6 Poor Metabolizer Phenotype May Be Associated With Risperidone Adverse Drug Reactions and Discontinuation
Abstract
OBJECTIVE: The cytochrome P450 2D6 (CYP2D6) enzyme metabolizes risperidone. CYP2D6 poor metabolizers have no CYP2D6 activity (7% of whites and 1%-2% of other races). This study tested whether the CYP2D6 poor metabolizer phenotype was associated with adverse drug reactions (ADRs) and discontinuation due to ADRs. METHOD: Adult inpatients and outpatients were recruited from July 2000 to March 2003 including (1) 325 who were stabilized on risperidone therapy and classified as either expressing moderate-to-marked ADRs (22%, 73/325) or not (78%, 252/325) and (2) 212 who discontinued risperidone and were classified as discontinued due to ADRs (38%, 81/212) or for other reasons (62%, 131/212). Genetic tests were performed by allele-specific polymerase chain reaction and/or by the AmpliChip CYP450 microarray system for up to 34 separate CYP2D6 alleles. Two logistic regression models with dependent variables (moderate-to-marked ADRs while taking risperidone and risperidone discontinuation due to ADRs) were evaluated with respect to the CYP2D6 phenotype. RESULTS: The odds ratios (ORs) and 95% confidence intervals (CIs) for the CYP2D6 poor metabolizer phenotype in the univariate analyses and after correcting for clinical variables were (1) OR = 3.1 (CI = 1.4 to 7.0) and 3.4 (CI = 1.5 to 8.0) for moderate-to-marked ADRs on risperidone and (2) OR = 3.0 (CI = 0.85 to 10.6) and 6.0 (CI = 1.4 to 25.4) for discontinuation due to ADRs. CONCLUSIONS: The CYP2D6 poor metabolizer phenotype appears to be associated with risperidone ADRs and discontinuation due to ADRs; however, this finding requires further study in larger patient populations. The CYP3A5 and p-glycoprotein exon 21 and 26 genotypes were not significantly associated with risperidone response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
To Err Is Human: Building a Safer Health System
(2000) · National Academies Press eBooks · doi:10.17226/9728 · Cited by 14,044
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,365
The Intraclass Correlation Coefficient as a Measure of Reliability
Bartko, J. J. (1966) · Psychological Reports · doi:10.2466/pr0.1966.19.1.3 · Cited by 2,299
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
ON THE METHODS AND THEORY OF RELIABILITY
BARTKO, J. J., & CARPENTER, W. T. (1976) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197611000-00003 · Cited by 1,310
Cascorbi, I. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114164 · Cited by 747
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Huang, M.-L., Peer, A. V., Woestenborghs, R., De Coster, R., Heykants, J., Jansen, A. A. I., Zylicz, Z., Visscher, H. W., & Jonkman, J. H. G. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.146 · Cited by 316
Dahl, M. L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M., & Sjöqvist, F. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10669-1 · Cited by 313
Pharmacogenetics of Antidepressant Medication Intolerance
Murphy, G. M., Kremer, C., Rodrigues, H. E., & Schatzberg, A. F. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.10.1830 · Cited by 283
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics
Boulton, D. W., DeVane, C. L., Liston, H. L., & Markowitz, J. S. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)01680-6 · Cited by 259
Uhr, M., Grauer, M. T., & Holsboer, F. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00074-x · Cited by 237
The American Psychiatric Publishing textbook of psychopharmacology
(2010) · Choice Reviews Online · doi:10.5860/choice.47-4164 · Cited by 233
Pharmacokinetics and drug interactions: update for new antipsychotics.
Ereshefsky, L. (1996) · PubMed · Cited by 211
Roberts, R. L., Joyce, P. R., Mulder, R. T., Begg, E. J., & Kennedy, M. A. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500099 · Cited by 202
The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement
van der Weide, J., Steijns, L. S. W., van Weelden, M. J. M., & de Haan, K. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00002 · Cited by 199
Comparison of Two CYP2D6 Genotyping Methods and Assessment of Genotype-Phenotype Relationships
Chou, W.-H., Yan, F., Robbins‐Weilert, D., et al. (2003) · Clinical Chemistry · doi:10.1373/49.4.542 · Cited by 121
Serum Concentrations and Side Effects in Psychiatric Patients During Risperidone Therapy
Olesen, O. V., Licht, R. W., Thomsen, E., Bruun, T., Viftrup, J. E., & Línnet, K. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199808000-00004 · Cited by 119
QTc Interval, CYP2D6 and CYP2C9 Genotypes and Risperidone Plasma Concentrations
LLerena, A., Berecz, R., Dorado, P., & de la Rubia, A. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042618 · Cited by 96
Potkin, S. G., Thyrum, P. T., Alva, G., Bera, R. B., Yeh, C., & Arvanitis, L. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200204000-00004 · Cited by 70
Pilot Study of the Cytochrome P450-2D6 Genotype in a Psychiatric State Hospital
de León, J., Barnhill, J. W., Rogers, T. J., Boyle, J., Chou, W. H., & Wedlund, P. J. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.9.1278 · Cited by 69
Self-citationOno, S., Mihara, K., Suzuki, A., Kondo, T., Yasui‐Furukori, N., Furukori, H., de Vries, R., & Kaneko, S. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1056-8 · Cited by 66
Optimal Dosing With Risperidone
Williams, R. P. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0411 · Cited by 66
Woestenborghs, R. J. H., Lorreyne, W., Rompaey, F. V., & Heykants, J. (1992) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(92)80556-6 · Cited by 60
Kirchheiner, J., Bertilsson, L., Bruus, H., Wolff, A., Roots, I., & Bauer, M. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-45136 · Cited by 55
Power and precision : a computer program for statistical power analysis and confidence intervals
Borenstein, M., Rothstein, H. R., & Cohen, J. (1997) · Medical Entomology and Zoology · Cited by 32
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Zhou, Y., Ingelman‐Sundberg, M., & Lauschke, V. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.690 · Cited by 583
Metadata
- Authors
- de Leon, J., Susce, M. T., Pan, R.-M., Fairchild, M., Koch, W. H., & Wedlund, P. J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-01-15
- Volume
- 66
- Issue
- 01
- Pages
- 15-27
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2029995473
- Cited by
- 319
- References
- 28
- FWCI
- 25.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.